Chairman & Chief Executive Officer Mr. Savas has served as Chairman and Chief Executive Officer of Alseres Pharmaceuticals, Inc. since September 2004. Prior to joining ALSE, Mr. Savas was Chairman, President and Chief Executive Officer of Aderis Pharmaceuticals, a privately held biopharmaceutical company headquartered in Hopkinton, MA. He undertook and completed a $45 million private placement at nearly double the valuation of the prior venture round, strengthened the Board of Directors, Scientific Advisory Board and management, culled out dead-end programs and revitalized and expanded corporate partnerships. Before joining Aderis, Mr. Savas was Chairman, President, and CEO of Unisyn Technologies, a company he refinanced, repositioned and subsequently merged with Cellex Biosciences. Before Unisyn, Mr. Savas served as Senior Vice President of Zymark Corporation, a laboratory automation company; Chairman, President and CEO of Xydex Corporation, a company he founded to in-license, develop, and commercialize novel separations technology which he subsequently sold to Genex Corporation. He was also Vice President and General Manager of Business Operations of the Continental Water Systems and the Waters Associates Divisions of Millipore Corporation. He serves on the Board of Directors of Sivida Corporation. Mr. Savas earned his BA in chemistry from Syracuse University.
|
Directors William Guinness joined the Board of Directors in July 2006. Mr. Guinness has been Chairman of Sibir Energy plc since 1999 and had additional roles with Pentex Energy plc and Pentex Oil plc. Mr. Guinness has been involved with various private venture capital operations, which cover areas as diverse as metal manufacturing, general aviation, and fine art consultancy. Mr. Guinness is also a director of a number of private companies involved in a wide range of commercial activities. Mr. Guinness previously served on the Company's Board of Directors from June 30, 2003 to September 20, 2003.
|
Director Mr. Mullen has been a member of the Board since June 2004. Mr. Mullen is currently the Chief Financial Officer of Magellan Biosciences, Inc., a clinical diagnostics company. From February 2003 to March 2006, Mr. Mullen was the Chief Financial Officer of JMH Capital, a private equity firm. From September 2000 to December 2002, Mr. Mullen was the Chief Financial Officer of Magellan Discovery Technologies, a private equity sponsored buyout firm. From March 1999 to September 2000, Mr. Mullen was the Chief Financial Officer and Director of Integration for the Analytical Instrument Strategic Business Unit of PerkinElmer, Inc., a provider of scientific instruments, consumables and services. From December 1995 to March 1999, Mr. Mullen was the Controller of Thermo Optek, a publicly traded subsidiary of Thermo Electron and manufacturer of spectroscopy instrumentation for molecular and elemental analysis. Mr. Mullen received his B.B.A from James Madison University.
|
= Chairman of the Board
= Chair
= Member
